Generic Medicine Info
Should be taken with food.
Hypersensitivity, history of serious ventricular or atrial arrhythmias, uncompensated cardiac insufficiency, congenital QT interval prolongation.
Special Precautions
Lactation; pregnancy; history of idiopathic hypertrophic subaortic stenosis, 2nd or 3rd ° AV block, cardiogenic shock; CHF; significant hypotension; severe left ventricular dysfunction; hypertrophic cardiomyopathy (especially obstructive); concomitant therapy with β-blockers or digoxin; oedema; increased intracranial pressure with cranial tumours; elderly; children <18 yr; impaired renal or hepatic function. Abrupt withdrawal may cause chest pain. Avoid use in patients in the immediate period postinfarction.
Adverse Reactions
Dizziness, nausea, dyspnea, bradycardia, oedema, palpitations, QT prolongation, CHF, nervousness, headache, drowsiness, psychiatric disturbances, insomnia, rash, sexual dysfunction, GI disturbances, weakness, tremor, paraesthesia, blurred vision, tinnitus, rhinitis, dyspnoea, cough, flu syndrome, diaphoresis, akathisia, arrhythmia, leukopenia, neutropenia, ventricular torsade de pointes.
Drug Interactions
Inhibits CYP206. Bioavailability increased by H2-blocker. Use with β-blockers may increase cardiac depressant effects on AV conduction. May increase serum levels/effects of carbamazepine, ciclosporin, digitalis, quinidine and theophylline. Concurrent use with fentanyl may increase hypotension.
CIMS Class
ATC Classification
C08EA02 - bepridil ; Belongs to the class of phenylalkylamine derivative non-selective calcium-channel blockers. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on bepridil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in